Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Fluxion Biosciences Expands IsoFlux Discovery Services Capabilities with Clinical Sample Procurement

Published: Monday, February 10, 2014
Last Updated: Monday, February 10, 2014
Bookmark and Share
New capability provides a full-service option for circulating tumor cell studies.

Fluxion Biosciences, Inc. announced a new capability to include full-service clinical sample procurement that will expand Fluxion’s IsoFlux Discovery Services offering. Fluxion currently offers a broad range of analytical services using its IsoFlux System for circulating tumor cell (CTC) enrichment, including qPCR and next-generation sequencing (NGS) based assays. With this new capability, Fluxion can now provide clinical sample procurement that includes fresh blood draws from a wide range of cancer indications and tumor subtype profiles, such as Her2+, KRAS+, and EGFR+ samples.

Fluxion’s Discovery Services are available to biopharmaceutical, diagnostic, and research institutes that wish to conduct CTC studies on a contract basis. These services are provided out of Fluxion’s South San Francisco reference laboratory and utilize the cutting-edge IsoFlux technology as well as the circulating tumor cell experience of Fluxion’s scientific personnel. With this new offering, clients can now specify the number and types of clinical samples they wish to analyze and have them included in the study without having to set up any clinical agreements. The clinical samples are shipped overnight to Fluxion’s laboratory and processed the day of arrival. Each sample is highly annotated with clinical information and obtained under IRB consent.

“After running our Discovery Services for some time now, we realized that obtaining prospective clinical samples for CTC studies is a major bottleneck for our clients. Setting up clinical agreements, obtaining IRB approval, and waiting for patient recruitment can slow things down considerably,” said Mike Schwartz, Program Director at Fluxion. “This new addition to our service offering will dramatically increase the speed of discovery for our clients, not to mention make it easier to source an entire study from a single vendor.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Fluxion Biosciences, UT Health Collaborate
Company has announced collaboration with UT Health to develop novel liquid biopsy approaches to improve the ability to diagnose, monitor, and treat cancer patients.
Saturday, April 30, 2016
Stanford University Study Shows Early Detection of CTCs in NSCLC Patients
IsoFlux System demonstrates high sensitivity CTC recovery in challenging patient group.
Tuesday, November 26, 2013
Scientific News
How it Works: Advanced Data Analysis Using Visualization
Visualisation of data can be used to help molecular biologists tackle the vast datasets their experiments create.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Molecular Origins of Dust Mite Allergy Discovered
Scientists have identified molecules of house dust mites that are targeted by the immune system of children, developing allergic rhinitis and asthma.
Influential Cancer Researcher Receives Agilent Thought Leader Award
Biologist Scott Lowe receives award in recognition for his contributions to cancer biology.
New Compound Shows Promise in Treating Multiple Human Cancers
The research presents a new way to efficiently kill these cancerous cells and holds promise for the treatment of all cancers.
ALS Study Reveals Role of RNA-Binding Proteins
The findings are a significant step forward in validating RNA-based therapy as a treatment for ALS.
Observing Direct Inheritance of Gene-Silencing RNA
Research has allowed for the observation of double-stranded RNA molecule being passed from parent to offspring in roundworms.
Using CRISPR to Accelerate Search for HIV Cure
Gene-editing platform makes it easier to create HIV-resistant immune cells.
IU Research Reveals Link between Molecular Mechanisms in Prostate Cancer and Ewing's sarcoma
Researchers at IU have suggested that the molecular mechanism that triggers the rare disease Ewing's sarcoma could act as a potential new direction for the treatment of more than half of patients with prostate cancer.
Tumor Markers Reveal Lethality Of Bladder Cancers
Researchers found that detection of certain tumor cells in early stage cancers helps identify high-risk cancers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos